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Abstract
Background: CDC25 phosphatases are important regulators of the cell cycle. Their abnormal expression detected in a 
number of tumors implies that their dysregulation is involved in malignant transformation. However, the role of 
CDC25s in vulvar cancer is still unknown. To shed light on their roles in the pathogenesis and to clarify their prognostic 
values, expression of CDC25A, CDC25B and CDC25C in a large series of vulvar squamous cell carcinomas were 
examined.
Methods: Expression of CDC25A, CDC25B, CDC25C and phosphorylated (phospho)-CDC25C (Ser216) were examined 
in 300 vulvar carcinomas using immunohistochemistry. Western blot analysis was utilized to demonstrate CDC25s 
expression in vulvar cancer cell lines. Kinase and phosphatase assays were performed to exclude cross reactivity among 
CDC25s isoform antibodies.
Results: High nuclear CDC25A and CDC25B expression were observed in 51% and 16% of the vulvar carcinomas, 
respectively, whereas high cytoplasmic CDC25C expression was seen in 63% of the cases. In cytoplasm, nucleus and 
cytoplasm/nucleus high phospho-CDC25C (Ser216) expression was identified in 50%, 70% and 77% of the carcinomas, 
respectively. High expression of CDC25s correlated significantly with malignant features, including poor differentiation 
and infiltration of vessel for CDC25B, high FIGO stage, presence of lymph node metastases, large tumor diameter, poor 
differentiation for CDC25C and high FIGO stage, large tumor diameter, deep invasion and poor differentiation for 
phospho-CDC25C (Ser216). In univariate analysis, high expression of phospho-CDC25C (Ser216) was correlated with 
poor disease-specific survival (p = 0.04). However, such an association was annulled in multivariate analysis.
Conclusions: Our results suggest that CDC25C and phospho-CDC25C (Ser216) play a crucial role and CDC25B a minor 
role in the pathogenesis and/or progression of vulvar carcinomas. CDC25B, CDC25C and phospho-CDC25C (Ser216) 
were associated with malignant features and aggressive cancer phenotypes. However, the CDC25s isoforms were not 
independently correlated to prognosis.
Background
Vulvar carcinoma, counting for 3-5% of all female genital
cancers [1], is a disease most frequently observed in elder
women. However, recently an increase in its incidence
was also seen among younger women [2,3]. Although sur-
gery is still kept as the standard treatment [3], consider-
able morbidity is often inevitably raised as a consequence
of radical surgery [4]. In a bid to decrease the incidence of
complications, there has been a movement towards indi-
vidualized therapy and less radical surgery. In this sense,
knowledge of biomolecular markers would be of consid-
erable value to yield a better treatment decision.
CDC25 phosphatases, which are believed to be impor-
tant regulators of cell cycle progression, dominate entry
into mitosis by regulating the activation of CDK1/cyclin
B [5]. Catalyzed by these dual specificity phosphatases,
cyclin/CDKs are dephosphorylated and actived after
removal of inhibitory phosphate groups from Thr14 and
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Tyr15 [6]. In human, three isoforms of CDC25 denoted
CDC25A, CDC25B and CDC25C exist. Initially,
CDC25A is found to act at the G1/S transition, whereas
CDC25B and CDC25C mainly play their roles at the G2/
M transition [5,7]. However, recent studies suggest that
all three CDC25 phosphatases function as regulators of
both G1/S and G2/M transitions [7].
Although exact reasons of tumorigenesis remain
unknown, it is believed that one of the hallmarks of tum-
origenesis is dysregulation of cell proliferation, and thus
is strongly suggested to be connected with disorders of
cell cycle [6,8-10]. CDC25s are implied to be involved in
the malignant transformation when deficient checkpoints
are performed during mitosis [6,11]. The activity of the
CDC25s are regulated by their phosphorylation status,
expression level and subcellular localization [6,11]. Previ-
ously, abnormal expression of CDC25s have been
reported in a number of carcinomas, such as breast [12],
ovarian [13], esophageal [14], prostate [15] and colorectal
carcinomas [9]. Overexpression of CDC25 isoforms are
supposed to contribute to tumorigenesis by enhancing
tumor malignancy [5]. To our knowledge, expression of
CDC25s in vulvar cancers has not yet been reported. The
aims of our study were to determine expression statuses
of CDC25A, CDC25B and CDC25C in a large series of
vulvar squamous cell carcinomas to shed light on their
roles in the pathogenesis of this cancer type and to clarify
their potential prognostic values.
Methods
Patient materials
A retrospective study including 300 cases of vulvar
squamous cell carcinoma was performed. These patients
underwent resection at The Norwegian Radium Hospital
from 1977 to 2006. The median age at diagnosis was 74
years (range 35-96 years). Pre-surgery treatment was
given to 9 patients, of which 6 received radiotherapy,
whereas the other 3 were treated with radiotherapy/che-
motherapy. Two hundred and one (67%) patients received
radical vulvectomy. Postoperative treatment including
irradiation, chemotherapy and irradiation/chemotherapy
were performed on 63 (21%), 3 (1%), and 4 (1%) of the
patients, respectively. Relapse was observed in 107 (36%)
patients. All patients were followed up since confirmed
diagnosis until death or 31. December, 2006. One hun-
dred and twenty (40%) patients died of vulvar cancer. The
median follow-up time for patients still alive was 131
months (range 11 to 346 months). All tumors were staged
based on the International Federation of Gynecology and
the Obstetrics (FIGO) classification [16]. Approval of the
study has been given by The Regional Committee for
Medical Research Ethics South of Norway (S-06012), The
Social- and Health Directorate (04/2639 and 06/1478)
and The Data Inspectorate (04/01043).
Histological specimens were reviewed by J.M.N, one of
the co-author, who was concealed from all clinical infor-
mation. Classification was performed according to World
Health Organization recommendations [17]. Two hun-
dred and eighty-two (94%) tumors were keratinizing/
nonkeratinizing, 14 (5%) were basaloid and 4 (1%) were
veruccoid. Previously, we have examined the expression
of 14-3-3σ and human papillomavirus (HPV) infection in
primary vulvar carcinomas [18,19], which was compared
with the expression of CDC25s from the present study.
Ten samples of normal vulva form patients undergoing
surgery for benign gynecological diseases were included
as control.
Cell Line
Two human vulvar squamous cell carcinoma cell lines,
SW-954 (ATCC, Manassas, VA, USA) and CAL-39
(DSMZ, Germany), were cultured in RPMI 1640 medium
(BioWhit-taker Europe, Verviers, Belgium) supplemented
with 5% fetal bovine serum (FBS) (Biochrom KG, Berlin,
Germany). For Western blot analysis and immunohis-
tochemistry, monolayer cells were harvested by 0.01 M
EDTA and thereafter washed in PBS.
Immunohistochemical method
Four-μm sections made from formalin-fixed, paraffin-
embedded tissues and cell lines were immunostained
using the Advance™ HRP System (K4068, Dako Corpora-
tion, CA, USA). After deparaffinization, sections for
CDC25A staining were microwaved in 10 mM Tris-1
mM EDTA, pH 9.0, sections for CDC25B and phospho-
CDC25C (Ser 216) staining were microwaved in 1 mM
EDTA, pH 8.0 and sections for CDC25C staining were
microwaved in 10 mM citrate buffer, pH 6.0 to regain the
epitopes blocked by formalin fixation. To block endoge-
neous peroxidase the sections were treated with 0.3%
hydrogen peroxide (H2O2) for 5 min. Sections were incu-
bated overnight at 4°C with monoclonal antibodies,
including CDC25A (clone DCS-120+DCS-121, 1:500, 0.4
μg IgG2a/ml), CDC25B (clone 25B03, 1:150, 1.3 μg IgG1/
ml), CDC25C (clone 25C07, 1:100, 2 μg IgG1/ml), all from
NeoMarkers, CA, USA, and phospho-CDC25C (Ser 216)
(clone 63F9, 1:500), from Cell Signaling, MA, USA. The
specimens were then given a sequential 30 min incuba-
tion with Advance™ HRP link and Adance HRP enzyme,
followed by treatment with 3'3-diaminobenzidine tetra-
hydrochloride (DAB) for 10 min, counterstained with
hematoxylin, dehydrated and mounted in Diatex.
Sections from tonsil with known CDC25A, CDC25B
and phospho-CDC25C (Ser 216) expression and from
breast carcinoma with known CDC25C expression were
used as positive control. Negative control included i) sub-
stitution of the monoclonal antibody with mouse myce-
loma protein of the same subclass and concentration asWang et al. BMC Cancer 2010, 10:233
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the monoclonal antibody, ii) incubation of sections with
phospho-CDC25C (Ser 216) absorbed with phospho-
CDC25C (Ser 216) peptide (Cell Signaling, MA, USA) as
recommended by the supplier.
Semiquantitative classes were used to describe the
intensity (absent, 0; weak, 1; moderate, 2; strong, 3) and
extent of staining (percent of positive tumor cells: absent,
0; < 10%, 1; 10-50%, 2; > 50%, 3). By multiplying intensity
score with extent score, product scores for both cyto-
plasm staining and nucleus staining were produced which
ranging from 0 to 9. By taking product scores from cyto-
plasm and nucleus into account at the same time, a com-
posed score was given for each section. Based on staining
pattern observed in normal vulvar epithelium, cutoff val-
ues in cytoplasm and/or nucleus were set. High CDC25A
and CDC25B immunostaining in the nucleus was classi-
fied with a score > 6, and low with a score ≤ 6, whereas,
high CDC25C and phospho-CDC25C (Ser 216) immu-
nostaining in cytoplasm was classified with a score > 3
and low with a score ≤ 3. In addition, high phospho-
CDC25C (Ser 216) immunostaining in nucleus was clas-
sified with a score > 0 and low with a score 0. Examina-
tion of immunostaining was performed by two
independent observers (Z.W. and R.H.) with no knowl-
edge of patient outcome. All discordant scores were
reviewed until final agreement was obtained.
Protein extraction
Protein extraction was performed as described previously
[20]. Cells were lysed in ice-cold NP-40 lysis buffer [1%
NP-40, 10% glycerol, 20 mM Tris-HCl, pH 7.5, 137 mM
NaCl, 100 mM sodium vanadate, 1 mM phenylmethylsul-
fonyl fluoride (PMSF) and 0.02 mg/ml each of aprotinin,
leupeptin, pepstatin, and 10 μl/ml phosphatase inhibitor
cocktail I (Sigma-Aldrich, St. Louis, MO)]. Lysates were
sonicated and clarified by centrifugation. Protein quanti-
tation was done by Bradford analysis. Twenty-five μg pro-
tein/lane was resolved by 12% SDS polyacrylamide gel
electrophoresis (PAGE) and then Transferred to PVDF
membranes.
Western blot analysis
The PVDF membranes with protein extract from cell
lines or 1 μg CDC25A, CDC25B and CDC25C antigens
(Upstate, NY, USA) were blocked with 5% nonfat dry milk
in tris-buffered saline-Tween (TBST) and subsequently
hybridized with antibodies against CDC25s [CDC25A,
1:200; CDC25B, 1:200, (Santa Cruz Biotechnology, CA,
USA); CDC25C, 1:200 and phospho-CDC25C (Ser 216),
1:500] overnight at 4°C, respectively. Membranes were
then washed in TBST for 3 times, with 10 mins each, and
further hybridized with corresponding anti-mouse or
anti-rabbit IgG conjugated with Horseradish Peroxidase
(HRP Labelled, 1:5000, 0.2 μg IgG1/ml dilution) for 1
hour at room temperature. After 3 times rince in TBST
for 10 mins each, membranes were finally treated by
Western Lightning Enhanced Chemiluminescence (ECL)
reagent (Perkin Elmer, MA, USA).
Nuclear and cytoplasmic extraction
The NE-REP nuclear and cytoplasmic Extraction
Reagents (Pierce Biotechnology, Rockford, USA) was
used to separate cytoplasm and nuclear proteins. West-
ern blot analysis on each fraction was performed as
described above. To confirm the pure separation of
nuclear and cytoplasmic fractions, Lamin B, a nuclear
protein exclusive recognizing antibody (Pierce Biotech-
nology), and Tubulin, a cytoplasmic protein exclusive rec-
ognizing antibody (Oncogene, San Diego, USA), were
used, respectively.
Protein dephosphorylation with CIAP
Proteins extracted from CAL-39 were dephosphorylated
by Calf intestinal alkaline phosphatase (CIAP) (Promega,
Madison, WI, USA). Proteins were treated by CIAP in a
50 μl reaction volume (protein 5 μg, CIAP 20 units, 10 ×
buffer 5 μl and H2O 42.5 μl). Following treatment for 30
min at 37°C, the reaction mixture was added an extra 20
units of CIAP and left for an additional 30 min at 37°C.
Untreated and CIAP treated proteins were separated by
SDS-PAGE and hybridized with CDC25C, phospho-
CDC25C (Ser 216), CDC25A and CDC25B antibodies,
respectively.
Antigen phosphorylation with CHK1
One μg antigen CDC25B was phosphorylated by CHK1
(Millipore, Billerica, MA, USA) in a 50 μl reaction volume
(antigen CDC25B 1 μg, CHK1 20 ng/μl, ATP 200 μM/μl,
10 × kinase buffer 5 μl and H2O 39 μl) for 30 min at room
temperature. Untreated and CHK1 treated antigens were
separated by SDS-PAGE, blotted onto PVDF membranes
and hybridized with CDC25B and phospho-CDC25C
(Ser 216) antibodies, respectively.
Statistical analyses
Pearson's chi-square (χ2) test was performed in order to
evaluate associations between CDC25 protein expression
and clinicopathologic variables. Kaplan and Meier esti-
mate and the log-rank test were used to evaluate and
compare survival data. Disease-specific survival was cal-
culated from the date of diagnosis to vulvar cancer
related death. A Cox proportional hazards regression
model was used for both univariate and multivariate eval-
uation of survival rates. In the multivariate analysis, a
backward stepwise regression was performed with a p =
0.05 as the inclusion criterion for variables in the univari-
ate analysis. All calculations were processed using SPSS
15.0 statistical software package (SPSS, Chicago, IL) and
statistical significance was considered as p ≤ 0.05.Wang et al. BMC Cancer 2010, 10:233
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Results
Specificity of antibodies
The specifity of CDC25 antibodies were tested by West-
ern blot analysis using the antigenes CDC25A, CDC25B
and CDC25C. However, since anti-CDC25B used for
immunohistochemistry was not recommended by the
supplier to use for Western blot analysis, an alternative
anti-CDC25B was utilized for Western blot analysis. Our
results showed that anti-CDC25A detected CDC25A, but
not CDC25B or CDC25C. Anti-CDC25B (only for West-
ern blot analysis) identified CDC25B, but not CDC25A or
CDC25C. Anti-CDC25C and anti-phospho-CDC25C
(Ser 216) immunoblotted with CDC25C, but not with
CDC25A or CDC25B (Figure 1a). These results indicate
that anti-CDC25A, anti-CDC25B, anti-CDC25C and
anti-phospho-CDC25C (Ser 216) specifically detect their
own respective antigen without any crossreaction with
other CDC25s isoform.
Anti-CDC25C, as well as anti-CDC25B, detected pro-
teins treated or un-treated with CIAP (Figure 1b), which
indicate that anti-CDC25C and anti-CDC25B recognize
their respective protein in phosphorylated as well as
dephosphorylated form. However, proteins treated with
C I A P  f a i l e d  t o  b e  i d e n t i f i e d  b y  a n t i - C DC 2 5 A  o r  a n t i -
phospho-CDC25C (Ser 216) (Figure 1b), which indicate
that both CDC25A and phospho-CDC25C (Ser 216) anti-
body exclusively detect phosphorylated CDC25A and
CDC25C, respectively.
Anti-CDC25B detected CDC25B antigen treated or un-
treated with CHK1, but neither of them was identified by
anti-phospho-CDC25C (Ser 216) (Figure 1c). Further-
more, no coexpression of CDC25B and phospho-
CDC25C (Ser216) was seen in serial sections of vulvar
carcinomas (Figure 1d-e). These results indicate that the
phospho-CDC25C (Ser 216) antibody does not cross-
react with phosphorylated CDC25B.
CDC25s protein expression
In normal vulvar squamous epithelium, nuclear mem-
brane staining for CDC25A was identified in basal, para-
basal, middle and top layers (10/10 cases with score 9),
whereas nuclear staining for CDC25B was seen in basal,
parabasal and middle layers (10/10 cases with score 6)
(Figure 2a-b). Cytoplasmic staining for CDC25C was
observed in basal, parabasal and middle layers (3/10 cases
with score 3 and 7/10 cases with score 6), whereas phos-
pho-CDC25C (Ser 216) was limited to the basal layer (7/
10 cases negative and 3/10 cases with score 3) (Figure 2c-
d). None of the normal cases showed nuclear staining for
CDC25C and phospho-CDC25C (Ser 216).
The immunostaining results in vulvar carcinomas are
summarized in Table 1. High CDC25A and CDC25B
immunostaining (score > 6) in the nucleus was observed
in 152/300 (51%) and 47/300 (16%) cases, respectively
(Figure 2e-f). CDC25A expression was observed in the
nuclear membrane. High CDC25C expression (score > 3)
in the cytoplasm was seen in 188/300 (63%) cases (Figure
2g). CDC25C immunostaining in the nucleus was not
observed in any cases. High phospho-CDC25C (Ser216)
expression in cytoplasm (score > 3) and nucleus (score >
0) were detected in 151/300 (50%) and 211/300 (70%)
cases, respectively. Taking both the cytoplasmic and
nuclear immunostaining into account, we found that high
phospho-CDC25C (Ser216) immunostaining (score > 3)
appeared in 232/300 (77%) cases (Figure 2h).
In the vulvar carcinoma cell lines SW-954 and CAL-39,
immunohistochemistry identified CDC25A (score = 3),
CDC25B (score = 9), CDC25C (score = 3) and phospho-
CDC25C (Ser216) (score = 3) in the nucleus, whereas,
CDC25B (score = 3), CDC25C (SW-954, score = 6 and
CAL-39, score = 9), and phospho-CDC25C (Ser216)
(score = 9) were observed in the cytoplasm (Figure 3a-d).
Similar results were detected using Western blot analysis
(Figure 3e). CDC25A was seen only in the nuclear frac-
tion. CDC25B was weakly expressed in the cytoplasmic
and strongly in the nuclear fraction. In contrast, CDC25C
and phospho-CDC25C (Ser 216) were strongly expressed
in the cytoplasmic fraction, but weakly in the nuclear
fraction.
Immunostaining results of CDC25s in relation to 
clinicopathological parameters
High expression of CDC25A in the nucleus was signifi-
cantly correlated to low expression of 14-3-3σ protein in
cytoplasm, nucleus and cytoplasm/nucleus (p = 0.03, p =
0.01 and p = 0.01, respectively) and to low expression of
phospho-CDC25C (Ser216) in nucleus and cytoplasm/
nucleus (p  = 0.002 and p  = 0.04, respectively). High
expression of CDC25B in the nucleus was significantly
correlated with poor differentiation (p  = 0.004), vessel
infiltration (p  = 0.03), high expression of phospho-
CDC25C (Ser216) in cytoplasm and cytoplasm/nucleus
(p = 0.01, and p = 0.04 respectively) and HPV infected
cases (p = 0.03). The levels of CDC25C and phospho-
CDC25C (Ser216) immunostaining in relation to clinico-
pathological parameters are shown in Table 2. High
expression of CDC25C in cytoplasm was significantly
correlated with high FIGO substage (p = 0.004), presence
of lymph node metastases (p = 0.04), large tumor diame-
ter (p = 0.03), poor differentiation (p = 0.03), high expres-
sion of 14-3-3σ protein in cytoplasm and cytoplasm/
nucleus (both p = 0.001) and high expression of phospho-
CDC25C (Ser216) in cytoplasm, nucleus and cytoplasm/
nucleus (all p  < 0.001). High expression of phospho-
CDC25C (Ser216) in cytoplasm, nucleus and cytoplasm/
nucleus were significantly correlated with high FIGO
substage (p = 0.05, p = 0.01 and p = 0.005, respectively),
large tumor diameter (p < 0.001, p = 0.009 and p < 0.001,Wang et al. BMC Cancer 2010, 10:233
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respectively), deep invasion (p = 0.01, p = 0.01 and p <
0.001, respectively), high 14-3-3σ protein levels in cyto-
plasm (p = 0.007, p < 0.001 and p < 0.001, respectively)
and high 14-3-3σ protein expression in cytoplasm/
nucleus (p = 0.005, p < 0.001 and p < 0.001, respectively).
Factors showing significant correlation with high expres-
sion of phospho-CDC25C (Ser216) in cytoplasm and
cytoplasm/nucleus were poor differentiation (p < 0.001
and p = 0.01, respectively). High nuclear expression of 14-
3-3σ was significantly correlated with high expression of
phospho-CDC25C (Ser216) in nucleus (p < 0.001) and
cytoplasm/nucleus (p = 0.002). Cases negative for HPV
was significantly correlation with high expression of
phospho-CDC25C (Ser216) in nucleus (p < 0.001).
In the univariate analysis only high expression of phos-
pho-CDC25C (Ser216) in cytoplasm/nucleus was associ-
Figure 1 Western blot analysis demonstrating specificty of CDC25s antibodies. (a) One μg of CDC25A (lane 1), CDC25B (lane 2) and CDC25C 
(lane 3) antigens were immunoblotted with CDC25A, CDC25B, CDC25C and phospho-CDC25C (Ser216) antibodies, respectively. (b) Untreated (lane 
1) and CIAP treated (lane 2) protein extracts from the vulvar cancer cell line CAL-39 were immunoblotted with CDC25A, CDC25B, CDC25C and phos-
pho-CDC25C (Ser216) antibodies, respectively. (c) One μg of CDC25B antigen untreated (lane 1) and treated (lane 2) with CHK1 immunoblotted with 
CDC25B and phospho-CDC25C (Ser216) antibodies, respectively. Immunohistochemical staining of CDC25B (d) and phospho-CDC25C (Ser216) (e) on 
serial sections of vulvar carcinomas.Wang et al. BMC Cancer 2010, 10:233
http://www.biomedcentral.com/1471-2407/10/233
Page 6 of 11
ated with poor disease-specific survival (p = 0.04) (Figure
4). However, in multivariate analysis, when phospho-
CDC25C (Ser216) cytoplasm/nucleus expression was
added to the variables lymph node metastases, tumor
diameter, infiltration of vessel, age and depth of invasion,
only lymph node metastases, tumor diameter, vessel infil-
tration and age retained independent prognostic signifi-
cance (Table 3).
Discussion
Overexpression of CDC25A has been reported in breast
[12], esophageal [14], hepatocellular [21], colorectal [9]
and ovarian carcinomas [13]. Therefore, abnormal
expression of CDC25A was implied as one of the poten-
tial oncogenic factors leading to dysregulation of cell
cycle control and consequently oncogenic transforma-
tion. However, in our study overexpression of CDC25A
was found not only in 51% of the vulvar carcinomas, but
also in normal vulvar squamous epithelium, indicating
that high expression of CDC25A is not important in the
pathogenesis of vulvar carcinomas. In agreement with
studies on thyroid [22] and colorectal carcinomas [9], we
found that disease-free survival was not significantly
associated with high expression of CDC25A, although
such an association was reported in breast [12], oesopha-
geal [14] and hepatocellular carcinomas [21]. These
results indicate that the role of CDC25A is cancer spe-
cific.
In our study, 16% of the vulvar carcinomas have higher
expression of CDC25B than normal vulvar squamous epi-
thelium. Previously, a wide range of CDC25B overexpres-
sion (20-79%) has been reported in many other cancer
types [5]. This discrepancy may be due to the various
tumor types studied. Overexpression of CDC25B in 16%
of our cases suggests that this protein may contribute to
tumorigenesis in a minority of vulvar carcinomas. We
failed to find an association with high CDC25B expres-
sion and disease-free survival, which was also reported in
studies on prostate [23], gastric [24], hepatocellular [21],
breast [12] and endometrial carcinomas. In contrast, a
positive correlation was found in colorectal [9] and ovar-
ian carcinomas [13]. These results suggest that contro-
Figure 2 Expression of CDC25 protein in vulvar squmous epithe-
lium. Immunohistochemical staining of CDC25A (a), CDC25B (b), 
CDC25C (c) and phospho-CDC25C (Ser216) (d) in normal vulvar epithe-
lium. CDC25A (e), CDC25B (f), CDC25C (g) and phospho-CDC25C 
(Ser216) (h) staining in vulvar carcinomas.
Table 1: Immunostaining results for CDC25s
Score CDC25A CDC25B CDC25C Phospho-CDC25C (Ser216)
Nucleus Nucleus Cytoplasm Cytoplasm Nucleus Cytoplasm 
and nucleus
n (%) n (%) n (%) n (%) n (%) n (%)
0 3 (1.0) 2 (0.7) 13 (4.3) 54 (18.0) 89 (29.7) 18 (6.0)
2 0 (0) 6 (2.0) 5 (1.7) 15 (5.0) 7 (2.3) 8 (2.7)
3 35 (11.7) 36 (12.0) 94 (31.3) 80 (26.7) 46 (15.3) 42 (14.0)
4 1 (0.3) 6 (2.0) 17 (5.7) 17 (5.7) 10 (3.3) 13 (4.3)
6 109 (36.3) 203 (67.7) 135 (45.0) 125 (41.7) 112 (37.3) 143 (47.7)
9 152 (50.7) 47 (15.7) 36 (12.0) 9 (3.0) 36 (12.0) 76 (25.3)
Total 300 (100.0) 300 (100.0) 300 (100.0) 300 (100.0) 300 (100.0) 300 (100.0)Wang et al. BMC Cancer 2010, 10:233
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versy still rests on CDC25B as a universal tumor marker
and that its prognostic value on gynaecologic carcinomas
seems limited.
In previous studies, overexpression of CDC25C has
been reported in a limited number of carcinomas. There-
fore, CDC25C was regarded as a less oncogenic factor
than CDC25A and CDC25B [5]. However, in the present
study high expression of CDC25C was observed in 63% of
vulvar carcinomas, a finding in line with studies on pros-
tate [15], colorectal [25] and endometrium carcinomas
[10]. The fact that overexpression of CDC25C was associ-
ated with advanced FIGO stage, presence of lymph node
metastases, large tumor diameter and poor differentia-
t i o n  i n d i c a t e  t h a t  h i g h  l e v e l  o f  C D C 2 5 C  i s  a n  e v e n t
occuring late in the tumor development. Our study failed
to show a positive correlation between overexpression of
CDC25C and disease-specific survival, which was similar
to the results reported in esophageal [26], pancreatic [27],
gastric [24] and ovarian carcinomas [13].
Compared to the low level of cytoplasmic phospho-
CDC25C (Ser 216) protein expression in basal layers of
normal vulvar squamous epithelium, high phospho-
CDC25C (Ser 216) protein expression was found in the
cytoplasm of 50% and in the nucleus of 70% of vulvar car-
cinomas. High expression of cytoplamic phospho-
CDC25C (Ser 216) was correlated with high level of cyto-
plasmic 14-3-3σ. This strengthens the theory that phos-
pho-CDC25C (Ser 216) protein sequestrated in the
cytoplasm due to binding of 14-3-3 lose its access to
nuclear CDK1/cyclin B complex, thus inhibiting mitotic
entry [5]. Unexpectly, high expression of nuclear phos-
pho-CDC25C (Ser 216) was correlated with high expres-
sion of nuclear 14-3-3σ protein. One hypothesis is that
phospho-CDC25C (Ser 216) in the nucleus is unable to
bind 14-3-3σ [28]. Phospho-CDC25C (Ser 216) will then
still stay in the nucleus and activate CDK1/cyclin B com-
plex, thus triggering G2/M transition. Therefore, high
nuclear expressions of phospho-CDC25C (Ser 216) in the
majority of cases indicate that phospho-CDC25C (Ser
216) may be important in the carcinogenesis of vulvar
carcinomas and would be a potential target for cancer
therapy.
According to the analyses between phospho-CDC25C
(Ser 216) and clinical parameters, high expression of
phospho-CDC25C (Ser 216) in cytoplasm/nucleus was
significantly correlated with advanced FIGO stage, large
tumor diameter and deep invasion as well as poor dis-
ease-specific survival. However, such an association
between phospho-CDC25C (Ser 216) expression in cyto-
plasm/nucleus and disease-specific survival was annulled
in multivariate analysis. The phospho-CDC25C (Ser 216)
has to our knowledge not been previously investigated in
any human cancer. Therefore, further studies are needed
to clarify the role of phospho-CDC25C (Ser 216) as a
prognostic marker.
In the present study, overexpression of CDC25A,
CDC25B and CDC25C isoforms was not significant asso-
ciated with each other, suggesting that overexpression of
multiple isoforms in vulvar carcinomas occur through
independent pathways [5]. However, high phospho-
CDC25C (Ser 216) expression was correlated with low
expression of CDC25A and high expression of CDC25B,
suggesting that the three can collaborate in the tumori-
genesis of a subset of vulvar carcinomas. Firstly, low
expression of CDC25A in 49% of vulvar, compared to its
high expression in normal tissues, might account for
DNA damage-induced G2 arrest which is accompanied
by proteasome-dependent destruction of CDC25A [7,29].
Figure 3 Expression of CDC25 protein in vulvar cancer cell line. Immunohistochemical staining of CDC25A (a), CDC25B (b), CDC25C (c) and phos-
pho-CDC25C (Ser216) (d) in CAL-39 cell line. Western blot analysis of CDC25s cellular localization in CAL-39 cells (e). Cell fractions of cytoplasm (lane 
1) and nucleus (lane 2) were immunoblotted with Tubulin and Lamin B antibodies to verify the purity of subcellular fraction extraction, then with 
CDC25A, CDC25B, CDC25C and phospho-CDC25C (Ser216) antibodies, respectively. Cyt: Cytoplasmic fraction; Nuc: Nuclear fraction.Wang et al. BMC Cancer 2010, 10:233
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Table 2: CDC25C and phospho-CDC25C (Ser216) immunostaining in relation to clinicopathological variables
Variables Total CDC25C Phospho-CDC25C (Ser216)
Cytoplasm Cytoplasm Nucleus
nL o w H i g h  ( % ) p1 Low High (%) p1 Low High (%) p1
Age 0.91 0.91 0.45
25-69 119 46 73 (61) 61 58 (49) 40 79 (66)
70-84 147 53 94 (64) 71 76 (52) 39 108 (74)
85+ 34 13 21 (62) 17 17 (50) 10 24 (71)
FIGO 0.004 0.05 0.01
I a 1 1 56  ( 5 5 ) 74  ( 3 6 ) 6 5  ( 4 6 )
Ib 35 23 12 (34) 24 11 (31) 17 18 (51)
II 110 38 72 (66) 55 55 (50) 25 85 (77)
III 121 38 83 (69) 55 66 (55) 32 89 (74)
IV 19 6 13 (68) 6 13 (68) 6 13 (68)
Not available 4
Lymph node metastases 0.04 0.14 0.54
None 136 58 78 (57) 78 58 (43) 40 96 (71)
Unilateral 76 21 55 (72) 33 43 (57) 19 57 (75)
Bilateral 34 9 25 (74) 16 18 (53) 7 27 (79)
Not available 54
Tumour diameter (cm) 0.03 < 0.001 0.009
0.3-2.5 90 41 49 (54) 60 30 (33) 35 55 (61)
2.6-4.0 94 34 60 (64) 46 48 (51) 21 73 (78)
4.1-20.0 100 27 73 (73) 35 65 (65) 21 79 (79)
Not available 16
Tumor differentiation 0.03 < 0.001 0.30
Well 74 37 37 (50) 51 23 (31) 18 56 (76)
Moderate 154 53 101 (66) 74 80 (52) 45 109 (71)
Poor 72 22 50 (69) 24 48 (67) 26 46 (64)
Depth of invasion (mm) 0.08 0.01 0.01
0.0-4.0 79 34 45 (57) 50 29 (37) 32 47 (60)
4.1-8.0 98 27 71 (72) 48 50 (51) 21 77 (79)
8.1-40.0 112 44 68 (61) 46 66 (59) 27 85 (76)
Not available 11
Infiltration of vessel 0.32 0.26 0.54
No 232 91 141 (61) 119 113 (49) 71 161 (69)
Yes 65 21 44 (68) 28 37 (57) 17 48 (74)
Not available 3
HPV2 0.29 0.09 < 0.001
Low (-) 167 57 110 (66) 99 68 (41) 32 135 (81)
High (+) 43 19 24 (56) 19 24 (56) 21 22 (51)
Not available 90Wang et al. BMC Cancer 2010, 10:233
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14-3-3σ cytoplasm2 0.001 0.007 < 0.001
Low (< 6) 83 43 40 (48) 52 31 (37) 39 44 (53)
High (≥ 6) 217 69 148 (68) 97 120 (55) 50 167 (77)
14-3-3σ nucleus2 0.40 0.48 < 0.001
Low (< 6) 123 42 81 (66) 58 65 (53) 51 72 (59)
High (≥ 6) 177 70 107 (61) 91 86 (49) 38 139 (79)
14-3-3σ cytoplasm/
nucleus2
0.001 0.005 < 0.001
Low (< 6) 75 40 35 (47) 48 27 (36) 36 39 (52)
High (≥ 6) 225 72 153 (68) 101 124 (55) 53 172 (76)
CDC25A 0.48 0.49 0.002
Low 148 52 96 (65) 77 71 (48) 31 117 (79)
High 152 60 92 (61) 72 80 (53) 58 94 (62)
CDC25B 0.87 0.01 0.13
Low 253 95 158 (63) 134 119 (47) 74 179 (71)
High 47 17 30 (64) 15 32 (68) 15 32 (68)
CDC25C - < 0.001 < 0.001
Low 112 - - - 76 36 (32) 47 65 (58)
High 188 - - - 73 115 (61) 42 146 (78)
1 Pearson chi-square
2 In previous reports, 14-3-3σ and HPV have been studied [18,19].
Table 2: CDC25C and phospho-CDC25C (Ser216) immunostaining in relation to clinicopathological variables (Continued)
Secondly, CDC25C phosphorylated at Ser 216 in
response to DNA damage [7] stay in the nucleus, instead
of being sequestrated in cytoplasm, and might still be able
to phosphorylate its substrate CDK1/cyclin B complex,
resulting in an un-thorough G2 arrest. This un-thorough
G 2  a r r e s t  m i g h t  b e  e n h a n c e d  b y  o v e r e x p r e s s i o n  o f
CDC25B which, other than A and C, was essential for
mitotic entry as cells recover from a DNA-induced
checkpoint arrest [7,30-33].
Our result showed that infection of HPV correlated
with high expression of CDC25B and nuclear phospho-
CDC25C (Ser216). This result is in agreement with previ-
ous studies of CDC25B, where CDC25B mRNA was
highly elevated in fibroblasts after being transformed by
SV-40 or by E6 or E7 papilloma virus transforming pro-
teins [5,34]. Little is known about CDC25C post-tran-
scriptional changes due to virally induced cellular
transformation. However, we found an increased
CDC25C protein expression in presence of HPV infec-
tion. In our study we could not demonstrate an associa-
tion between CDC25A protein and HPV infection,
although an elevated mRNA level and enzyme activity of
CDC25A was found in quiescent human fibroblasts
infected with the EIA adenovirus protein [35]. These
findings suggest that CDC25s promoters may be specifi-
cally targeted by viruses during the cell transformation
process [5] and that CDC25B and CDC25C may be sub-
jected to HPV regulation.
Human CDC25 proteins consist of two domains: the N-
terminal regulatory domain where the three isoforms
share 20-25% identity and the C-terminal catalytic
domain sharing approximately 60% identity [7]. Due to
the similarity in the structure, antibodies to CDC25A,
CDC25B and CDC25C have a high potential to not only
identify their specific antigen, but also the other two iso-
forms. We found that the four CDC25 antibodies used in
the present study detected their own respective antigen
without any cross-reaction with the other CDC25s,
strengthening the trustiness of our results. In contrast,
previous papers have used CDC25s antibodies for immu-
nohistochemistry without knowing the specificity of their
antibodies [8,10,14,22,23,27,36,37], which may partly
explain the conflicting results regarding cellular localiza-
tion of CDC25A, CDC25B and CDC25C [6].
Interestingly, a different immunostaining pattern was
seen between the two CDC25C antibodies in vulvar car-
cinomas. By using anti-CDC25C, which recognized both
phosphorylated and dephosphorylated forms, immunos-
taining was detected only in cytoplasm, whereas anti-
phospho-CDC25C (Ser 216), which only recognizes
phosphorylated form, immunostained both in cytoplasm
and nucleus. Previously, it has been reported that six
amino acids are homologous in the phospho-CDC25C
(Ser 216) and phospho-CDC25B (Ser323) domain [38].
Therefore, we were led to believe that the nuclear immu-
nostaining observed by using anti-phospho-CDC25CWang et al. BMC Cancer 2010, 10:233
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Page 10 of 11
(Ser 216) was false due to cross-reaction with phospho-
CDC25B (Ser323). However, this was not the case, since
we excluded the possibility that anti-phospho-CDC25C
(Ser 216) cross-react with phosphorylated CDC25B by
the kinase test and immunostaining. On serial sections,
no coexpression was observed between phospho-
CDC25C (Ser 216) and CDC25B, both phosphorylated
and dephosphorylated forms. Therefore, we speculated
that in vulvar carcinomas the epitope in the phospho-
CDC25C (Ser 216) domain supposed to be recognized by
anti-CDC25C (phosphorylated and dephosphorylated)
may be masked for some unknown reasons resulting in
lost nuclear staining.
Conclusions
Our results suggest that CDC25C and phospho-CDC25C
(Ser216) play a crucial role and CDC25B a minor role in
the development and/or progression of vulvar carcino-
mas. CDC25B, CDC25C and phospho-CDC25C (Ser216)
expression were associated with malignant features and
aggressive cancer phenotypes. However, the CDC25s iso-
forms were not independently correlated to prognosis.
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Table 3: Relative risk (RR) of dying from vulvar cancer
Variables Univariate analysis Multivariate analysis
RR 95% CIa p RR 95% CIa p
Lymph node 
metastases
2.49 1.92-3.23 < 0.001 2.18 1.64-2.90 < 0.001
Tumour 
diameter
1.78 1.40-2.25 < 0.001 1.47 1.10-1.95 0.009
Infiltration of 
vessel
2.42 1.64-3.57 < 0.001 1.76 1.10-2.82 0.02
Age 1.60 1.22-2.10 0.001 1.46 1.03-2.08 0.03
Phospho-
CDC25C 
(Ser216)b
1.64 1.02-2.64 0.04 - - -
a 95% confidence interval
b Cytoplasma/nucleus: low ≤ 3 and high > 3
Figure 4 Survival curves using the Kaplan-Meier method. Kaplan-
Meier curve of disease-specific survival in relation to phospho-CDC25C 
(Ser216) protein expression levels in cytoplasm/nucleus (p = 0.04) for 
the entire series (n = 300).Wang et al. BMC Cancer 2010, 10:233
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